Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ ( treprostinil ) inhalation powder for Patients Suffering with PAH and PH-ILD
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
| Ticker |
Sentiment |
Impact |
|
LQDA
|
Somewhat Bullish
|
24 %
|
|
UTHR
|
Neutral
|
11 %
|
